Awiqli® Approved in the US, the First and only Once-Weekly Basal Insulin Treatment for Adults with Type 2 Diabetes

Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first

How to Ease Type 2 Diabetes Burnout

Living with type 2 diabetes can be stressful and exhausting. There’s so much to keep up with to manage your blood sugar (glucose) and overall health. “People may feel overwhelmed by monitoring glucose, medication schedules, food decisions, and concerns about complications,” says Barbara Eichorst, RD, CDCES , vice president of health programs at the American Diabetes Association (ADA). That feeling of being overwhelmed can become so severe that s…

FDA Approves First Once-Weekly Insulin for Type 2 Diabetes

Novo Nordisk’s icodec-abae is now approved in the US for type 2 diabetes only, after a prior rejection partly due to concerns about hypoglycemia in type 1 diabetes.

Novo Nordisk receives FDA approval for basal insulin Awiqli

Novo Nordisk has received FDA approval for Awiqli injection 700 units/mL, a basal insulin for adults with type 2 diabetes.

Awiqli approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes

The approval offers the only once‑weekly basal insulin option, providing a new treatment solution that fits different patient routines and preferences for adults living with type 2 diabetes